Irinotecan, also known by its brand name Camptosar, is used mainly as a second-line treatment for colorectal cancer. The FDA recommends screening patients for a gene that could make them more susceptible to the harmful side effects of the drug, the most worrisome of which is neutropenia, an abnormally low number of white blood cells.
In a paper published in the Aug. 28, 2007 Journal of the National Cancer Institute, UNC researchers analyzed data from nine previous studies of irinotecan. They found that patients who received a medium or high dose of the drug had greater risk of neutropenia if they had two copies of a variation of the gene UGT1A1, known as UGT1A1*28. At lower doses, however, the risk was the same regardless of what UGT1A1 gene the patients had.
“Many institutions saw the FDA’s recommendation as a mandate to test all patients before treating them with irinotecan even though many clinicians didn’t think it was always necessary given that low doses of the drug weren’t causing problems,” said Howard McLeod, Pharm.D., senior author of the study and director of the UNC Institute for Pharmacogenomics and Individualized Therapy.
“Our review showed that at low doses the drug is well tolerated and can be taken by most people,” McLeod said. “As the dosage increases, genetics become a larger factor in determining what side effects patients experience, and then testing becomes essential.”
Having a genetic test available for a medicine is valuable, but so is knowing when to use that test, said Dr. Richard Goldberg, a co-author of the study and physician in chief of the North Carolina Cancer Hospital.
“There are so many treatment options for cancer patients that the more information we have about matching the right therapy to the patient, the better off we all are,” Goldberg said. “Studies like this one give oncologists the tools needed to take better care of patients while avoiding tests and expenses that aren’t needed.”
The authors recommended that the FDA amend the product information for irinotecan to describe the association between irinotecan dose and risk of hematologic toxicity among patients with two UGT1A1*28 genes.
Clinton Colmenares | EurekAlert!
When a fish becomes fluid
17.12.2018 | Institute of Science and Technology Austria
Some brain tumors may respond to immunotherapy, new study suggests
11.12.2018 | Columbia University Irving Medical Center
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
18.12.2018 | Materials Sciences
18.12.2018 | Physics and Astronomy
18.12.2018 | Physics and Astronomy